| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 80 |
| 1 | NIVOLUMAB | 29 |
| 2 | CARBOPLATIN | 19 |
| 3 | IPILIMUMAB | 16 |
| 4 | LENVATINIB | 13 |
| 5 | PACLITAXEL | 12 |
| 6 | PACLITAXEL (AIBUMIN-BOUND) | 12 |
| 7 | ATEZOLIZUMAB | 11 |
| 8 | PEMETREXED DISODIUM | 11 |
| 9 | PEMETREXED | 10 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | BEVACIZUMAB-MALY | 1 | 0.0050 |
| 1 | LAROTRECTINIB | 1 | 0.0011 |
| 2 | PEMBROLIZUMAB | 80 | 0.0007 |
| 3 | AVELUMAB | 3 | 0.0007 |
| 4 | GLUTATHIONE | 1 | 0.0006 |
| 5 | ENFORTUMAB VEDOTIN | 4 | 0.0005 |
| 6 | CEMIPLIMAB-RWLC | 1 | 0.0005 |
| 7 | INSULIN LISPRO-AABC | 1 | 0.0005 |
| 8 | TREMELIMUMAB | 2 | 0.0005 |
| 9 | DOSTARLIMAB | 1 | 0.0004 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CTLA-4-directed Blocking Antibody [EPC] | 18 | 0.0004 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 29 | 0.0003 |
| 2 | Programmed Death Ligand-1 Blocker [EPC] | 4 | 0.0002 |
| 3 | Glinide [EPC] | 1 | 0.0001 |
| 4 | CD19-directed Chimeric Antigen Receptor [EPC] | 1 | 0.0001 |
| 5 | Platinum-based Drug [EPC] | 23 | 0.0001 |
| 6 | Microtubule Inhibitor [EPC] | 12 | 0.0001 |
| 7 | Sphingosine 1-phosphate Receptor Modulator [EPC] | 1 | 0.0001 |
| 8 | Penem Antibacterial [EPC] | 2 | 0.0001 |
| 9 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 6 | 0.0000 |